(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 2MM | -3% |
Operating Income | 1.2MM | -119% |
Operating Expenses | 861K | -90% |
Net Income | -7.8MM | +33% |
R&D | 5.6MM | +11% |
Interest Expense | 1.6K | -85% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]
A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.
On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery. The company released the mixed topline data in February 2024. The presentation included MELODY-1 Phase 3 data results, which indicate that the Intent-to-Treat PL9643 treatment population demonstrated
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 pivotal clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery (ASCRS).
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced results for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).
Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript February 15, 2024 Palatin Technologies, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $-0.43. Palatin Technologies, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome […]
Q2 2024 Palatin Technologies Inc Earnings Call
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal second quarter ended December 31, 2023.
Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets.
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).